Data for Riociguat have been presented at the ATS 2009 International Conference

May 15 - 20, 2009
San Diego, USA

Data from a phase II trial with Riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension have been presented at the American Thoracic Society (ATS) International Conference.


Tuesday, May 19, 2009:
Investor Conference Call - Review of Riociguat phase II data

with

Prof. Hossein Ardeschir Ghofrani, University Hospital of Giessen and Marburg, Germany
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Gerrit Weimann, Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Background Information
About RiociguatDownload ( PDF, 52 KB ) collect
Riociguat Clinical Trial ProgramDownload ( PDF, 67 KB ) collect
About Pulmonary HypertensionDownload ( PDF, 53 KB ) collect



Abstract on Riociguat at the ATS 2009 International Conference

Riociguat Dose Titration in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or Pulmonary Arterial Hypertension (PAH), [Publication Page: A3337]

Last updated: January 07, 2014 Copyright © Bayer AG